Precision obesity medicine framework guides individualized GLP-1, dual, and triple agonist selection across lifespan | Research

The takeaway

Framework for phenotype-guided obesity pharmacotherapy across all ages uses patient-specific metabolic, psychological, and complication profiles to select from GLP-1RAs, dual GIP/GLP-1, triple agonists, and combination strategies.

Right drug for right patient
Precision framework matches specific obesity drug mechanisms to individual patient phenotypes—moving beyond one-size-fits-all pharmacotherapy

What the researchers found

Phenotype-guided framework: matches drug mechanism to patient profile. Drug options: GLP-1RA, GIP/GLP-1 (tirzepatide), triple agonists, combinations. Patient factors: metabolic, psychological, complications, age. Across lifespan: pediatric to elderly.

Why it matters

With 10+ obesity drugs available or emerging, clinicians need guidance on which drug to prescribe for which patient. This framework provides the first systematic approach to personalized obesity pharmacotherapy.

How the study worked

Narrative review proposing a precision medicine framework for obesity pharmacotherapy.

What this study cannot tell us

Proposed framework—not validated in prospective studies. Evidence for some phenotype-drug matches is limited. Pediatric data sparse. Framework complexity may limit practical adoption.

How to read the evidence

Narrative review proposing a framework. Evidence-based recommendations where available.

When this study was published

Published in 2025.

The bigger picture

Precision medicine in obesity is now possible with diverse drug options. This framework could become a template for obesity treatment guidelines worldwide.

Questions still open

Can this framework be validated in prospective clinical studies?
Which phenotype-drug matches have the strongest evidence?
Would AI-based decision tools operationalize this framework?

Common questions

How do doctors choose which obesity drug to prescribe?

This framework proposes matching the drug to the patient: considering metabolic type (insulin resistance vs not), psychological factors (binge eating, depression), specific complications (heart failure, liver disease), and age. Different drugs work through different mechanisms and may be better for different patient profiles.

Are obesity drugs one-size-fits-all?

No—and that is the key insight of this framework. With GLP-1 drugs, dual agonists (tirzepatide), and triple agonists (retatrutide) each working through different mechanisms, the right choice depends on the individual patient's specific obesity phenotype, complications, and goals.

Read the original research

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.

Journal of endocrinological investigation, 48(12), 2761-2798

View on PubMed ↗Publisher’s paper ↗

Citation

Tuccinardi, Dario; Masi, Davide; Watanabe, Mikiko; Zanghi Buffi, Valeria; De Domenico, Francesco; Berti, Sabrina; Cipriani, Valentina; Manco, Melania; Manfrini, Silvia; Pagotto, Uberto. (2025). Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.. Journal of endocrinological investigation, 48(12), 2761-2798. https://doi.org/10.1007/s40618-025-02700-7